InSite and Senju collaborate to develop and market azithromycin ophthalmic solution using DuraSite

NewsGuard 100/100 Score

InSite Vision Incorporated (OTCBB:INSV) and Senju Pharmaceutical Co., Ltd. today announced that they have entered into a collaboration and license agreement to develop and market InSite's azithromycin ophthalmic solution using DuraSite® including AzaSite® 1% and AzaSite XtraTM 2% ocular antibiotics in Japan. Senju has agreed to pay InSite an upfront license fee, additional development milestones fees, and a percentage royalty on net sales.

"We are pleased to enter this strategic partnership with one of the leading ophthalmic pharmaceutical companies in Japan," said Timothy Ruane, Chief Executive Officer of InSite Vision. "We look forward to the approval of these important ocular antibiotics for the benefit of the Japanese people."

Source:

Senju Pharmaceutical Co., Ltd.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
API processes in the pharmaceutical industry